Only in recent decades, antibodies against MOG (MOG-IgG) have been identified in people who were previously diagnosed with various other autoimmune-neurological diagnoses such as multiple sclerosis (MS), aquaporin-4-antibody (AQP4-IgG) seronegative neuromyelitis optica spectrum disorder (NMOSD), and acute disseminated encephalomyelitis (ADEM), as well as in isolated and recurrent optic neuritis (ON) and transverse myelitis (TM) (2–6). This evidence concerns the gene AQP4 and myeloid sarcoma.